PHOTOSTABILITY DETERMINATION OF COMMERCIALLY AVAILABLE NIFEDIPINE ORAL DOSAGE FORMULATIONS

被引:38
|
作者
GRUNDY, JS [1 ]
KHERANI, R [1 ]
FOSTER, RT [1 ]
机构
[1] UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI,EDMONTON,AB T6G 2N8,CANADA
关键词
ARTIFICIAL SUNLIGHT; GITS; HPLC; NIFEDIPINE; PHOTODEGRADATION; PHOTOSTABILITY;
D O I
10.1016/0731-7085(94)00100-6
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Nifedipine (NIF), a 1,4-dihydropyridine calcium channel antagonist, undergoes photodegradation to dehydronifedipine (DNIF) upon exposure to ultraviolet (UV) light and to the nitroso analogue of dehydronifedipine (NDNIF) when exposed to sunlight. NIF photodegradation products do not contribute to clinical activity, thus the content of NIF must remain uniform between equipotent formulations. Large differences in light stability between bioequivalent NIF products could potentially result in the therapeutic failure of unstable preparations. Consequently, if large photostability differences do exist between NIF preparations, product substitution may not be warranted. The light stability of 10 intact immediate- or controlled-release oral NIF formulations, obtained from several European and North American manufacturers, was studied using direct continuous artificial sunlight exposure extending over a 12-week period. The content of both NIF and NDNIF for each product was measured to determine the extent of photodecomposition using a specific and sensitive reversed-phase high pressure liquid chromatographic (HPLC) method. In addition, NIF photodegradation was measured using both pure NIF powder and methanolic NIF solution to determine the effectiveness of the artificial sunlight source used in this study. After 12 weeks of artificial sunlight exposure, less than 3% of NDNIF (w/w initial NIF content) was present in each of the 10 tested dosage forms. Photodegradation was greater than 10% (w/w initial NIF content) in similar to 5-10 min (mean t(1/2) = 31 min), and in similar to 24 h (mean t(1/2) = 7.7 days) of artificial sunlight exposure for methanolic NIF solution and pure NIF powder samples; respectively. Therefore, the tested NIF formulations all appear to be-photostable up to at least 12 weeks of continuous artificial sunlight exposure, compared with pure NIF powder and methanolic NIF solution. It is concluded that if therapeutic failures or pharmacodynamic differences between the tested NIF formulations were observed, photoinstability as a major contributory factor would be unlikely.
引用
收藏
页码:1529 / 1535
页数:7
相关论文
共 50 条
  • [1] Pediatric drugs - A review of commercially available oral formulations
    Strickley, Robert G.
    Iwata, Quynh
    Wili, Sylvia
    Dahl, Terrence C.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (05) : 1731 - 1774
  • [3] RELATIVE BIOAVAILABILITY OF COMMERCIALLY AVAILABLE IBUPROFEN ORAL DOSAGE FORMS IN HUMANS
    GILLESPIE, WR
    DISANTO, AR
    MONOVICH, RE
    ALBERT, KS
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (09) : 1034 - 1038
  • [4] Comparative effects of various commercially available mouthrinse formulations on oral malodour
    Saad, S.
    Greenman, J.
    Shaw, H.
    [J]. ORAL DISEASES, 2011, 17 (02) : 180 - 186
  • [5] In vitro gastric survival of commercially available probiotic strains and oral dosage forms
    Caillard, Romain
    Lapointe, Nicolas
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) : 125 - 127
  • [6] A review of formulations of commercially available antibodies
    Strickley, Robert G.
    Lambert, William J.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (07) : 2590 - +
  • [7] Composition of commercially available glucagon formulations
    Tuca, Alexandru
    Ajsic, Amra
    Tschaikner, Mathias
    Deutsch, Felix
    Jungklaus, Miro
    Troetzmueller, Martin
    Koefeler, Harald
    Pieber, Thomas
    Regittnig, Werner
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 : S154 - S155
  • [8] Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules
    Winiarski, Aleksander P.
    Infeld, Martin H.
    Tscherne, Ronald
    Bachynsky, Maria
    Rucki, Richard
    Nagano-Mate, Kathy
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2007, 47 (06) : 747 - 755
  • [9] Effect of food on the comparative bioavailability of two commercially available sustained-release tablet formulations containing nifedipine
    Qato, MK
    Mohammed, FA
    [J]. STP PHARMA SCIENCES, 1998, 8 (06): : 369 - 373
  • [10] Sprinkle formulations——A review of commercially available products
    Han Sol Lee
    Jeong-Jun Lee
    Myeong-Gyu Kim
    Ki-Taek Kim
    Cheong-Weon Cho
    Dae-Duk Kim
    Jae-Young Lee
    [J]. Asian Journal of Pharmaceutical Sciences, 2020, 15 (03) : 292 - 310